Bristol-Myers Squibb (BMY)
Develops medicines for cancer, blood disorders, immunology, cardiovascular disease and neuroscience.
$62.35
vs last close−0.27 (−0.43%)
Something off on this page? Send us feedback.
Next report
Oct 29, 26
in 37 days
EPS estimate
$1.68
Revenue estimate
$12.62B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25Apr '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$1.67$1.80$1.46$1.63$1.26$1.58$2.04Pending
Estimate$1.47$1.49$1.09$1.52$1.23$1.42$1.60$1.68
Surprise+13.6%+20.8%+33.9%+7.2%+2.4%+11.3%+27.5%—
RevenueReportedEstimate
Feb '25Apr '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$12.34B$11.20B$12.27B$12.22B$12.50B$11.49B$12.97BPending
Estimate$11.57B$10.70B$11.44B$11.85B$12.28B$10.93B$11.74B$12.62B
Surprise+6.7%+4.7%+7.2%+3.1%+1.8%+5.1%+10.5%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $1.31 | — | — |
| Sep 2028 | $1.31 | — | — |
| Jun 2028 | $1.41 | — | — |
| Mar 2028 | $1.22 | — | — |
| Dec 2027 | $1.61 | — | — |
| Sep 2027 | $1.53 | — | — |
| Jun 2027 | $1.67 | — | — |
| Mar 2027 | $1.45 | — | — |
| Dec 2026 | $1.60 | — | — |
| Oct 2026 | $1.68 | — | — |
| Jul 2026 | $1.60 | $2.04 | +27.5% |
| Apr 2026 | $1.42 | $1.58 | +11.3% |
| Feb 2026 | $1.23 | $1.26 | +2.4% |
| Oct 2025 | $1.52 | $1.63 | +7.2% |
| Jul 2025 | |||
| Apr 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Jul 2024 | |||
| Apr 2024 | |||
| Feb 2024 | |||
| Oct 2023 | |||
| Jul 2023 | |||
| Apr 2023 | |||
| Feb 2023 | |||
| Oct 2022 | |||
| Jul 2022 | |||
| Apr 2022 | |||
| Feb 2022 | |||
| Oct 2021 | |||
| Jul 2021 | |||
| Apr 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Jan 2019 | |||
| Oct 2018 | |||
| Jul 2018 | |||
| Apr 2018 | |||
| Feb 2018 | |||
| Oct 2017 | |||
| Jul 2017 | |||
| Apr 2017 | |||
| Jan 2017 | |||
| Oct 2016 | |||
| Jul 2016 | |||
| Apr 2016 | |||
| Jan 2016 | |||
| Oct 2015 | |||
| Jul 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $1.31 | — | — | $10.25B | — | — | — |
| Sep 2028 | $1.31 | — | — | $10.17B | — | — | — |
| Jun 2028 | $1.41 | — | — | $10.30B | — | — | — |
| Mar 2028 | $1.22 | — | — | $9.80B | — | — | — |
| Dec 2027 | $1.61 | — | — | $12.52B | — | — | — |
| Sep 2027 | $1.53 | — | — | $12.04B | — | — | — |
| Jun 2027 | $1.67 | — | — | $12.12B | — | — | — |
| Mar 2027 | $1.45 | — | — | $11.16B | — | — | — |
| Dec 2026 | $1.60 | — | — | $12.66B | — | — | — |
| Oct 29, 2026 | $1.68 | — | — | $12.62B | — | — | — |
| Jul 30, 2026 | $1.60 | $2.04 | +27.5% | $11.74B | $12.97B | +10.5% | +2.8% |
| Apr 30, 2026 | $1.42 | $1.58 | +11.3% | $10.93B | $11.49B | +5.1% | +5.2% |
| Feb 5, 2026 | $1.23 | $1.26 | +2.4% | $12.28B | $12.50B | +1.8% | +3.3% |
| Oct 30, 2025 | $1.52 | $1.63 | +7.2% | $11.85B | $12.22B | +3.1% | +7.1% |
| Jul 31, 2025 | |||||||
| Apr 24, 2025 | |||||||
| Feb 6, 2025 | |||||||
| Oct 31, 2024 | |||||||
| Jul 26, 2024 | |||||||
| Apr 25, 2024 | |||||||
| Feb 2, 2024 | |||||||
| Oct 26, 2023 | |||||||
| Jul 27, 2023 | |||||||
| Apr 27, 2023 | |||||||
| Feb 2, 2023 | |||||||
| Oct 25, 2022 | |||||||
| Jul 27, 2022 | |||||||
| Apr 29, 2022 | |||||||
| Feb 4, 2022 | |||||||
| Oct 27, 2021 | |||||||
| Jul 28, 2021 | |||||||
| Apr 29, 2021 | |||||||
| Feb 4, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 7, 2020 | |||||||
| Feb 6, 2020 | |||||||
| Oct 31, 2019 | |||||||
| Jul 25, 2019 | |||||||
| Apr 25, 2019 | |||||||
| Jan 24, 2019 | |||||||
| Oct 25, 2018 | |||||||
| Jul 26, 2018 | |||||||
| Apr 26, 2018 | |||||||
| Feb 5, 2018 | |||||||
| Oct 26, 2017 | |||||||
| Jul 27, 2017 | |||||||
| Apr 27, 2017 | |||||||
| Jan 26, 2017 | |||||||
| Oct 27, 2016 | |||||||
| Jul 28, 2016 | |||||||
| Apr 28, 2016 | |||||||
| Jan 28, 2016 | |||||||
| Oct 27, 2015 | |||||||
| Jul 23, 2015 |